The "hunger hormone" ghrelin and its effect in the brain is also the subject of the interview, as is the explanation of why ghrelin alone is not suitable for drug treatment. For this purpose, the researchers are working with combinations of intestinal hormones, some of which can be synthesized in hormone-like molecules.
Combinations of hormone signals in a single molecule, so-called polyagonists, are currently being tested in phase II and III clinical trials and could be approved as active substances this year.
Detailed information in the interview in the Helmholtz Newsroom.